Avicenna Alliance: enhanced knowledge, improved decisions, better outcomes
FULL MENU

Cancer & In Silico Oncology Task Force

Cancer & In Silico Oncology Task Force

BACK

Cancer & In Silico Oncology Task Force

Mission: Accelerate, optimize and personalize cancer treatment through the development, clinical validation and clinical translation of in silico methods

Cancer is such a complex global threat that the European Commission has included it in the list of the five prioritized research missions of the Horizon Europe research and innovation programme for the years 2021-2027.

As a branch of the Avicenna Research & Technology WG, the Cancer and In Silico Oncology TF has the objective to accelerate, optimize and personalize cancer treatment through the development, clinical validation and clinical translation of in silico methods.

Goals

  • Develop clinically driven and overseen digital twins of tumour growth and tumour and organism response to cancer treatment interventions.
  • Ensure trustworthiness, explainability, robustness, stability and good quality of component interconnection for all underying mechanistic and/or AI and/or hybrid models.
  • Technically and clinically validate cancer digital twins through formal clinical studies, including clinical trials.
  • Translate cancer digital twins into clinical practice, following certification
  • Monitor and evaluate the clinical use of certified cancer digital twins and further exploit the latter for in silico clinical trials and broader clinical research.


Georgios Stamatakos

Georgios Stamatakos

Co-Chair of the Cancer & In Silico OncologyTask Force

Research Professor, National Technical University of Athens (NTUA)

READ BIO

NEWS

News The European Parliament voted the reform of General Pharmaceutical Legislation (GPL)

The European Parliament voted the reform of General Pharmaceutical Legislation (GPL)

On April 10, the European Parliament overwhelmingly backed the reform of General Pharmaceutical Legislation (GPL), marking a pivotal moment in healthcare regulation. With a resounding majority, both the Directive and Regulation were embraced, reflecting a collaborative effort within the ENVI committee.

News The Avicenna Alliance warmly welcomes Tox By Design into its esteemed ranks!

The Avicenna Alliance warmly welcomes Tox By Design into its esteemed ranks!

Tox by Design is a prominent European toxicological expertise firm specializing in conducting toxicological Risk Assessments (RAs) for various industries such as biotech, pharmaceuticals, cosmetics, medical devices, and API synthesis.

News Marc Horner is the new Avicenna International Affairs Working Group Leader

Marc Horner is the new Avicenna International Affairs Working Group Leader

We are thrilled to announce that Marc Horner, Distinguished Engineer at Ansys, and Global Harmonization Task Force leader at the Avicenna Alliance, has been appointed as the new International Affairs Working Group Leader. Marc was already acting as a close partner of Nathalie Virag, former head of the International Affairs Working Group, recently appointed by Medtronic to prestigious responsibilities.

Sign up for our monthly newsletter!

Sign up for our monthly newsletter!

Fill in the fields you find below

Avicenna Alliance is an initiative of:

Avicenna VPH

© 2018-2024 Avicenna Alliance | powered by We Berry